Free Analysis

Data-driven stock analysis, valuation deep dives, and financial forensics. Every article backed by the numbers.

Market SignalsCOP/ Energy

Three Energy Names At Different Cycle Phases: COP, EOG, SLB

Conoco, EOG, and Schlumberger sit at three different points on the energy capex cycle. The Signals Desk maps where each franchise is and which one offers the best risk-adjusted setup for the next 18 months.

A sector scan across one E&P major, one US shale specialist, and one oilfield services franchise. The three names produce very different cash flow profiles. The buy point depends on which cycle phase you believe is most attractive.

Revisiting Our Chevron Fair Value Call As The Hess Integration Settles

Our earlier 'Chevron fair value' argument pegged the equity at $165-180 with the Hess integration as the principal catalyst. The deal closed, the Guyana exposure is consolidated, and revenue compressed in fiscal 2025. We update the framework.

Market SignalsNVDA

Revisiting Our Nvidia Thesis: The Bull Case Just Got Louder

Our earlier 'Five Trillion' narrative argued Nvidia was being underpriced for the AI capex cycle. Since publication, free cash flow has reached $96.7 billion, the multiple has held, and Wall Street's biggest AI bull just got louder. We update the thesis.

Procter & Gamble's Defensive Premium Is Less Defensive Than The Market Thinks

The consensus has been buying P&G as a safe defensive name through the consumer cycle. Underneath the headline, volume growth has been flat to negative for six quarters, emerging market FX exposure is widening, and the dividend coverage is tightening. The premium is mispriced.

Why The Street Is Wrong About Tesla's $15 Trillion Optimus Number

The latest Elon Musk pitch puts Optimus at a $15 trillion opportunity. Tesla shares trade at a 399 times P/E and a $1.66 trillion market cap that already incorporates a substantial Optimus optionality. The Risk Desk dismantles the math.

Inside Merck's Keytruda Cliff Strategy

Keytruda is the largest single oncology product in pharma history. It will lose primary patent protection in 2028. Merck's strategy to replace the revenue runs across subcutaneous formulation, label expansion, M&A, and a deep clinical pipeline. The Research Desk walks the full plan.

Inside Deere's Precision Agriculture Pivot

Deere finished fiscal 2025 with revenue down 12 percent year-over-year and net income compressed to $5.0 billion. The cycle has turned. The longer-term story is the precision agriculture platform, which now produces recurring software-like revenue and is changing the franchise's earnings durability. The Research Desk goes deep.

Five Things The Market Is Missing About AbbVie

AbbVie's reported 2025 net income of $4.2 billion masks the underlying earnings power. Free cash flow of $17.8 billion tells a different story. The Valuation Desk lists five things consensus is underweighting on this name.

Five Risks At Johnson & Johnson The Market Is Underpricing

The pharma franchise is doing the work, but the consolidated balance sheet, the talc litigation overhang, and the medical device segment exposure to FDA leadership turnover deserve more weight in the equity case.

Visa vs Mastercard: The Cross-Border Volume Question

Both networks have produced compound earnings growth above 12 percent annually for the past five years. The differentiating variable for the next 24 months sits in cross-border volume mix, where Mastercard now leads on growth rate. The question for the equity is whether that gap closes or widens.

Costco vs Walmart: Which Retail Giant Deserves The Premium

Costco trades at 54 times trailing earnings against Walmart at 48 times. Both have delivered superior comparable sales. Both have invested heavily in supply chain. Only one of the two has membership economics that justify the multiple gap. This is our framework for picking.

Caterpillar's Tariff Question Is Bigger Than Margin

Wall Street is asking whether Caterpillar can sustain mid-cycle margins through the current tariff regime. The Risk Desk view: the tariff hit on consolidated EBIT is approximately 200-300 basis points and is not the binding constraint. The cycle is.

Market SignalsPFE

Pfizer's Arvinas Deal Adds A Protein-Degradation Bet To The Pipeline

The licensing deal announced this week with Arvinas via Rigel adds an estrogen receptor degrader to the breast cancer pipeline. The bigger picture: Pfizer is paying for pipeline replacement at a moment when the patent cliff is six quarters away.

Capital AllocationMCD

McDonald's Company-Run Margin Question Is The Story Of The Year

A research note this week flagged the gap between McDonald's company-operated and franchised margins. The 75 percent franchised mix gives the franchise its capital-light profile, but the 25 percent company-operated piece is doing more work than the headline numbers suggest.

Capital AllocationGS

Goldman's Capital Return Engine Is Doing The Quiet Compounding

Net income recovered to $17.2 billion in 2025, the highest reported result since 2021. Return on tangible equity sits north of 14 percent, the buyback yield is approaching 4 percent, and the multiple has barely budged. The argument writes itself.

Disney's Parks Capex Cycle Is The Single Biggest Risk To The Thesis

Capital expenditure jumped 48 percent in fiscal 2025 to $8 billion as Disney rebuilds the parks footprint. Free cash flow held up, but the next two years of capex commitments will compress it materially. The Risk Desk view: the multiple is not priced for the squeeze.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36